Sol-Gel Technologies is an experienced dermatology company developing advanced treatments for patients with rare skin conditions.

Sep 30, 2024 · Sol-Gel reported a net loss of $0.4 million for the third quarter of 2024 and loss of $0.01 per basic and diluted share, compared to a net loss of $5.7 million and a loss of $0.21 per basic and diluted share for the same period in 2023.

May 16, 2024 · Sol-Gel developed TWYNEO, which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older, and EPSOLAY, which is approved by the FDA for the treatment of inflammatory lesions of rosacea in adults.

Jul 12, 2024 · Sol-Gel developed TWYNEO, which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older, and EPSOLAY, which is approved by the FDA for the treatment of inflammatory lesions of rosacea in adults.

Sol-Gel Technologies announces FDA approval of TWYNEO®. Sol-gel.com. July 27, 2021. Accessed August 22, 2023. https://ir.sol-gel.com/news-releases/news-release-details/sol-gel-technologies-announces-fda-approval-twyneor.

Jun 28, 2021 · Sol-Gel is developing tapinarof cream, 1%, aiming to offer product formulation innovations and increased affordability for patients compared to the brand expected to be launched; Our proof-of-concept study for SGT-210 (erlotinib gel) in palmoplantar keratoderma patients has been completed and indicated a possible modest improvement

Jan 27, 2023 · Patidegib, an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if approved by the FDA; Phase 3 study expected to initiate in the second half of 2023, with results expected by the end of 2025

Jan 27, 2023 · Sol-Gel developed TWYNEO which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, which is approved by the FDA for the treatment of inflammatory lesions of rosacea in adults.

Sol-Gel Technologies is an experienced dermatology company that is leveraging innovative approaches to develop advanced treatments for patients with severe skin conditions.

Sol-Gel’s marks and logos and all other proprietary identifiers used by Sol-Gel in connection with the Site (“Sol-Gel’s Trademarks”) are all trademarks and/or trade names of Sol-Gel, whether or not registered.